Atlas Trials

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Clinical trial NCT06006273 · RECRUITING

Trial details

NCT number
NCT06006273
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Refractory Solid Tumors
Start date
2023-08-16
Primary completion
2026-12-31
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.